|
|
Recent Developments in the Management of Invasive Fungal Infections |
|
1) Fungus in Focus II: An Update from ICAAC and IDSA 2007
2) Rational Use of Antifungal Prophylaxis in High-Risk Patients
|
Program Overview
|
- Dr. Thomas Patterson and Dr. James Lewis discuss the latest research on diagnostics, antifungal resistance, treatment strategies, and drug safety presented at the 2007 meetings of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA). Insights on the upcoming IDSA guidelines for Candida and Aspergillus infections are also discussed.
- Dr. Richard Drew and Dr. John Perfect evaluate clinical study results recently published in an article in the New England Journal of Medicine titled, "Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia." During the course of their discussion, Dr. Drew and Dr. Perfect discuss the rational use of antifungal prophylaxis in high-risk patients and how patient management may evolve in the coming years due to improved diagnostic techniques.
|
Target Audience |
This activity has been designed to meet the needs of pharmacists and all other healthcare professionals who care for and who may be involved in the diagnosis, management, and treatment of invasive fungal infections.
|
Learning Objectives |
At the conclusion of this activity, participants should be better able to:- Identify key treatment strategies included in the upcoming IDSA guidelines for Candida and Aspergillus infections
- Recognize which high-risk patient populations may benefit with using a mold-active agent for antifungal prophylaxis
|
Faculty |
James S. Lewis, PharmD
Infectious Diseases Pharmacy Programs Manager
Clinical Assistant Professor
University Health System, Department of Pharmacy
University of Texas Health Science Center, San Antonio
San Antonio, Texas
Thomas F. Patterson, MD
Professor of Medicine
The University of Texas Health Science Center
San Antonio, Texas
Richard H. Drew, PharmD
Professor of Pharmacy
Campbell University School of Pharmacy
Associate Professor of Medicine
Duke University School of Medicine
Durham, North Carolina
John R. Perfect, MD
Professor of Medicine
Duke University Medical Center
Durham, North Carolina
|
Pharmacist Accreditation |
 The American Academy of CME (Academy) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Academy has assigned 1 contact hour (0.1 CEU) of continuing pharmacy education credit to this activity. ACPE Universal Program Number: 297-999-07-029-HO1-P.
|
| Release Date: Tuesday, December 11, 2007 |
| Expiration Date: Wednesday, December 10, 2008 |
Estimated Time to Complete Activity: 1 hour
|
Disclosure Statement |
According to the disclosure policy of the Academy, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of the Academy to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.
|
Disclosures |
James S. Lewis, PharmD serves as a consultant and a member of the Speakers Bureau for Astellas, Pfizer, and Schering-Plough.
Thomas F. Patterson, MD has received research support from Astellas Pharma US Inc., Enzon, Merck & Co, Nektar Therapeutics, Pfizer, and Schering-Plough Corporation; Dr. Patterson was the principal investigator and the funds were paid to his institution. Additionally, he serves as a consultant to Astellas Pharma US Inc., Basilea, Merck & Co, Pfizer, Schering-Plough Corporation, and Stiefel Laboratories and is a member of the Speakers Bureau for Astellas Pharma US Inc., Merck & Co, Pfizer, and Schering-Plough Corporation.
Richard H. Drew, PharmD has received research support from Cubist, NeuTec, and Schering-Plough. He serves as a consultant for Merck, Schering-Plough, and Theravance. Also, he is a speaker for Enzon, Ortho-McNeil, Sanofi-Aventis, and Schering-Plough Corporation.
John R. Perfect, MD has received research support from Astellas, Enzon, Merck, Pfizer, and Schering-Plough. Dr. Perfect was the principal investigator and the funds were paid to Duke, his institution. Additionally, Dr. Perfect serves as a scientific consultant for Astellas, Enzon, Merck, Pfizer, and Schering-Plough and he serves on the scientific advisory board for Astellas, Enzon, Merck, Pfizer, and Schering-Plough.
Planning Committee Members: Karen Wetzel, American Academy of CME and Vesna Drenovac, RPh, MS, and Marco Cicero, PhD, Vemco MedEd have disclosed that they have no relevant financial relationships with any commercial interests.
|
Off-label Disclosure Statement |
At the time of release of this CE activity, the following non-FDA approved off-label uses of the following products are discussed in “Fungus in Focus II: An Update from ICAAC and IDSA 2007”: PCR assay for diagnostic purposes; voriconazole for pediatric use at doses of 7 mg/kg; caspofungin for pediatric use; combination therapy for aspergillosis and zygomycosis.
At the time of the release of this CE activity, the following off-label uses of the following antifungal agents are discussed in “Rational Use of Antifungal Prophylaxis in High-Risk Patients”: itraconazole (for prophylaxis); voriconazole (for prophylaxis).
|
Fee |
There is no fee to participate in this educational activity.
|
Method of Participation |
|
Please note that you must listen to both programs to receive credit. To receive credit for your participation in this CE podcast activity, please complete the following steps:
- Review the CE information for both programs including the target audience, learning objectives, and disclosures.
- Listen to and review both programs carefully.
- Complete the CE Post-test, selecting the most appropriate response to each question.
- Complete the CE Evaluation Form and Credit Information.
- Fax the Evaluation Form and Credit Information to (609) 921-6428 or mail to: American Academy of CME, 186 Tamarack Circle, Skillman, NJ 08558. Documentation of credit will be mailed within 6-8 weeks following receipt of your materials.
|
|
Hardware/Software Requirements
|
| All educational activities are accessible via Internet Explorer and Netscape browsers. A high speed
connection is highly recommended. Windows Media Player, sound card, and speakers are required for
audio. You must have Adobe Acrobat Reader version 4 or above installed on your computer to view PDF
files. If you do not have Acrobat Reader, you can download it for free at Adobe.com |
|
|
Jointly sponsored by the American Academy of CME, Inc. and Vemco MedEd, LLC
Supported by an educational grant from Schering-Plough Corporation
|
|
podcasts
